Merck (MRK) Common Equity (2009 - 2026)

Merck (MRK) has 18 years of Common Equity data on file, last reported at $45.9 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $45.9 billion, down 5.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.9 billion (down 5.1% YoY), and the FY2025 annual result was $52.6 billion, up 13.44% from the prior year.
• Common Equity retreated to $45.9 billion in Q1 2026 per MRK's latest filing, from $52.6 billion in the prior quarter.
• Over five years, Common Equity peaked at $52.6 billion in Q4 2025 and troughed at $37.6 billion in Q4 2023.
• A 5-year average of $44.8 billion and a median of $44.6 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity surged 51.46% in 2022, then decreased 18.29% in 2023.
• A 5-year view of Common Equity shows it stood at $46.1 billion in 2022, then fell by 18.29% to $37.6 billion in 2023, then grew by 23.22% to $46.4 billion in 2024, then advanced by 13.44% to $52.6 billion in 2025, then retreated by 12.69% to $45.9 billion in 2026.
• Business Quant data shows MRK's Common Equity at $45.9 billion in Q1 2026, $52.6 billion in Q4 2025, and $51.9 billion in Q3 2025.